产品中心 抗体 配对抗体

所有图片(1/1)

IL-15 Recombinant Rabbit mAb (SDT-1596-11)

货号: S0B3353

Datasheet COA
  • 价格: 询价
  • 规格:
  • 数量:
斯达特大包装询价 大包装询价

产品介绍 评论(0)

产品规格
  • 宿主来源

    Rabbit
  • 抗原名称

    IL-15
  • 免疫原

    Recombinant Protein
  • Accession

    P40933
  • 克隆号

    SDT-1596-11
  • 抗体类型

    Recombinant mAb
  • 抗体同种型

    IgG
  • 应用

    Sandwich ELISA
  • 反应种属 ?

    Hu
  • 交叉反应

    No cross-reactivity against IL-2

  • 纯化方式

    Protein A
  • 浓度

    2 mg/ml
  • 纯度

    >95% by HPLC
  • 标记

    Unconjugated
  • 性状

    Liquid
  • 缓冲体系

    PBS pH7.4, 0.03% Proclin 300

  • 储存条件

    12 months from date of receipt, 2 to 8 °C as supplied

  • 稀释度

    [{"application": "ELISA", "dilution": "", "species": ""}, {"application": "Sandwich ELISA", "dilution": "", "species": ""}, {"application": "CLIA", "dilution": "", "species": ""}, {"application": "Lateral Flow", "dilution": "", "species": ""}, {"application": "Dot Blot", "dilution": "", "species": ""}, {"application": "WB", "dilution": "", "species": ""}, {"application": "IP", "dilution": "", "species": ""}, {"application": "IHC-P", "dilution": "", "species": ""}, {"application": "ICC", "dilution": "", "species": ""}, {"application": "IF", "dilution": "", "species": ""}, {"application": "ICFCM", "dilution": "", "species": ""}, {"application": "FCM", "dilution": "", "species": ""}, {"application": "mIHC", "dilution": "", "species": ""}]
背景介绍
  • Interleukin-15 (IL-15) is a pleiotropic cytokine discovered in 1994, belonging to the 4-α helix bundle family of cytokines, which also includes IL-2. It plays a critical role in the immune system, particularly in the activation, proliferation, and survival of immune cells such as T cells, natural killer (NK) cells, and NKT cells. Its unique signaling mechanisms and broad biological functions make it a critical focus in immunology and immunotherapy research. IL-15 has emerged as a promising candidate for immunotherapy, particularly in cancer treatment. Its ability to enhance NK and T cell responses without inducing activation-induced cell death (AICD) makes it a favorable alternative to IL-2. Recent advancements include the development of IL-15 superagonists like N-803, which has been approved by the FDA for treating non-muscle-invasive bladder cancer.

  • 配对推荐

    评论(0)

      共 0 条
      • 1
      共计0页,前往